--- title: "NP47926 Biologic, Biosimilar's and Methotrexate Injections" ocid: "ocds-r6ebe6-0000841676" canonical_url: "https://d3tenders.com/contract/?ocid=ocds-r6ebe6-0000841676" markdown_url: "https://d3tenders.com/contract/ocds-r6ebe6-0000841676.md" json_url: "https://d3tenders.com/contract/ocds-r6ebe6-0000841676.json" source: "Public Contracts Scotland" current_stage: "Tender" buyer: "The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland)" published: "2026-09-21" --- # NP47926 Biologic, Biosimilar's and Methotrexate Injections Buyer: The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland) Current stage: Tender OCID: ocds-r6ebe6-0000841676 [View canonical contract page](https://d3tenders.com/contract/?ocid=ocds-r6ebe6-0000841676) [Download OCDS JSON](https://d3tenders.com/contract/ocds-r6ebe6-0000841676.json) ## Summary Public Services Delivery Scotland, the Common Services Agency’s central purchasing body, is procuring biologic, biosimilar and methotrexate medicines for NHS Scotland. The requirement covers adalimumab, etanercept, golimumab, infliximab for intravenous infusion and subcutaneous injection, omalizumab, tocilizumab, ustekinumab, tildrakizumab, and methotrexate in 25mg/1ml and 50mg/1ml pre-filled injection devices and syringes. The procurement is divided into 12 product lots, with NHS Scotland health bodies and Integrated Joint Boards as the intended delivery organisations across Scotland. It is a medicines supply opportunity rather than a clinical service or construction contract. Electronic ordering and payment arrangements will support supply to the participating NHS organisations. The buyer has reached tender and invited offers through an open procedure, with electronic submission. Tenders must be submitted by 21 October 2026 at 12:00 UTC; bids are opened at the same time. The estimated value is £334,866,015 covering a 24-month framework term and a possible extension of up to a further 24 months. Lots are awarded either to one supplier or as unranked multi-supplier frameworks, with between three and nine framework participants permitted depending on the product; the framework maximum is 18 participants. Bids may be submitted for any number of lots and product variants are not allowed. Evaluation is weighted 95% price and 5% quality, based on API sources. The framework is covered by the Government Procurement Agreement. This opportunity suits pharmaceutical manufacturers, marketing-authorisation holders, wholesalers and specialist medicines suppliers able to supply the named biologic, biosimilar or methotrexate products at NHS scale. For every medicine tendered, bidders must hold a current UK Marketing Authorisation approved by the MHRA, using a PL, PLGB or PLPI number. The organisation and any subcontractors must hold valid BS EN ISO 9001 certification or an equivalent quality standard. Products must comply with MHRA best-practice guidance on labelling and packaging, with samples supplied when requested. Bidders must provide a climate-change plan covering actions to reduce emissions and agree to support community benefits in Scotland, either through proposed activity or engagement with NHS Scotland’s Community Benefits Gateway. Strong price competitiveness is central because price carries 95% of the evaluation. ## Notice Supply of Biologics, Biosimilars and Methotrexate Injections to NHS Scotland. ### Lot Information Methotrexate (25mg/1ml concentration) Pre-Filled Self Injection Device Supply of Methotrexate (25mg/1ml concentration) Pre-Filled Self Injection Device to NHS Scotland. The Authority intends to award this Lot as an unranked multi-supplier framework per product line to a maximum of 3 Framework Participants. Full details of Goods and volumes can be found within the ITT documents. Renewal: This framework includes the option to extend for any number of periods, up to a maximum overall period of 24 months upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire. Infliximab Subcutaneous Injection Supply of infliximab subcutaneous injection to NHS Scotland. The Authority intends to award this Lot as a single supplier framework per product line. Full details of Goods and volumes can be found within the ITT documents. Renewal: This framework includes the option to extend for any number of periods, up to a maximum overall period of 24 months upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire. Methotrexate (25mg/1ml concentration) Pre-Filled Self Injection Syringe Supply of Methotrexate (25mg/1ml concentration) Pre-Filled Self Injection Syringe to NHS Scotland. The Authority intends to award this Lot as an unranked multi-supplier framework per product line to a maximum of 3 Framework Participants. Full details of Goods and volumes can be found within the ITT documents. Renewal: This framework includes the option to extend for any number of periods, up to a maximum overall period of 24 months upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire. Methotrexate (50mg/1ml concentration) Pre-Filled Self Injection Device Supply of Methotrexate (50mg/1ml concentration) Pre-Filled Self Injection Device to NHS Scotland. The Authority intends to award this Lot as an unranked multi-supplier framework per product line to a maximum of 3 Framework Participants. Full details of Goods and volumes can be found within the ITT documents. Renewal: This framework includes the option to extend for any number of periods, up to a maximum overall period of 24 months upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire. Methotrexate (50mg/1ml concentration) Pre-Filled Syringe Supply of Methotrexate (50mg/1ml concentration) Pre-Filled Syringe to NHS Scotland. The Authority intends to award this Lot as an unranked multi-supplier framework per product line to a maximum of 3 Framework Participants. Full details of Goods and volumes can be found within the ITT documents. Renewal: This framework includes the option to extend for any number of periods, up to a maximum overall period of 24 months upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire. Adalimumab Supply of adalimumab to NHS Scotland. The Authority intends to award this Lot as an unranked multi-supplier framework per product line to a maximum of 7 Framework Participants. Full details of Goods and volumes can be found within the ITT documents. Renewal: This framework includes the option to extend for any number of periods, up to a maximum overall period of 24 months upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire. Etanercept Supply of etanercept to NHS Scotland. The Authority intends to award this Lot as an unranked multi-supplier framework per product line to a maximum of 5 Framework Participants. Full details of Goods and volumes can be found within the ITT documents. Renewal: This framework includes the option to extend for any number of periods, up to a maximum overall period of 24 months upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire. Golimumab Supply of golimumab to NHS Scotland. The Authority intends to award this Lot as an unranked multi-supplier framework per product line to a maximum of 4 Framework Participants. Full details of Goods and volumes can be found within the ITT documents. Renewal: This framework includes the option to extend for any number of periods, up to a maximum overall period of 24 months upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire. Infliximab Intravenous Infusion Supply of infliximab intravenous infusion to NHS Scotland. The Authority intends to award this Lot as an unranked multi-supplier framework per product line to a maximum of 6 Framework Participants. Full details of Goods and volumes can be found within the ITT documents. Renewal: This framework includes the option to extend for any number of periods, up to a maximum overall period of 24 months upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire. Omalizumab Supply of omalizumab to NHS Scotland. The Authority intends to award this Lot as an unranked multi-supplier framework per product line to a maximum of 4 Framework Participants. Full details of Goods and volumes can be found within the ITT documents. Renewal: This framework includes the option to extend for any number of periods, up to a maximum overall period of 24 months upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire. Tocilizumab Supply of tocilizumab to NHS Scotland. The Authority intends to award this Lot as an unranked multi-supplier framework per product line to a maximum of 5 Framework Participants. Full details of Goods and volumes can be found within the ITT documents. Renewal: This framework includes the option to extend for any number of periods, up to a maximum overall period of 24 months upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire. Ustekinumab Supply of ustekinumab to NHS Scotland. The Authority intends to award this Lot as an unranked multi-supplier framework per product line to a maximum of 9 Framework Participants. Full details of Goods and volumes can be found within the ITT documents. Renewal: This framework includes the option to extend for any number of periods, up to a maximum overall period of 24 months upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire. Tildrakizumab Supply of tildrakizumab to NHS Scotland. The Authority intends to award this Lot as a single supplier framework per product line. Full details of Goods and volumes can be found within the ITT documents. Renewal: This framework includes the option to extend for any number of periods, up to a maximum overall period of 24 months upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire. ## Key Details | Field | Value | | --- | --- | | Publication source | Public Contracts Scotland | | Latest notice | https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=SEP564879 | | Notice type | OJEU - F2 - Contract Notice | | Procurement type | Framework | | Procurement category | Goods | | Procurement method | Open | | Procurement method details | Open procedure | | Tender suitability | Not specified | | Awardee scale | Not specified | | All stages | Tender | ## Dates | Field | Value | | --- | --- | | Publication date | 21 Sep 2026 | | Submission deadline | 21 Oct 2026 | | Future notice date | Not specified | | Award date | Not specified | | Contract period | Not specified | | Recurrence | Not specified | ## Values | Field | Value | | --- | --- | | Tender value | £334,866,015 | | Lots value | £334,866,016 | | Awards value | Not specified | | Contracts value | Not specified | ## Status | Field | Value | | --- | --- | | Tender status | Active | | Lots status | Active | | Awards status | Not specified | | Contracts status | Not specified | ## Buyer | Field | Value | | --- | --- | | Main buyer | The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland) | | Locality | EDINBURGH | | Postcode area | Edinburgh | | Postcode | EH12 9EB | | Country | Scotland | | ITL 1 | TLM Scotland | | ITL 2 | TLM1 East Central Scotland | | ITL 3 | TLM13 City of Edinburgh | | Local authority | City of Edinburgh | | Electoral ward | Drum Brae/Gyle | | Westminster constituency | Edinburgh South West | | Delivery location | TLM Scotland | ## CPV Codes ### Divisions - 33 - Medical equipments, pharmaceuticals and personal care products ### Codes - 33600000 - Pharmaceutical products - 33650000 - General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents - 33652000 - Antineoplastic and immunomodulating agents - 33690000 - Various medicinal products ## Release History - 21 Sep 2026 at 01:00 - Tender - OJEU - F2 - Contract Notice - https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=SEP564879 ## Documents - https://www.publiccontractsscotland.gov.uk/search/show/search_view.aspx?ID=SEP564879 NP47926 Biologic, Biosimilar's and Methotrexate Injections - Supply of Biologics, Biosimilars and Methotrexate Injections to NHS Scotland. ## Notice URLs - http://publicservicesdelivery.scot/about/procurement/ - http://www.publiccontractsscotland.gov.uk/info/InfoCentre.aspx?ID=2343 - http://www.publiccontractsscotland.gov.uk/info/InfoCentre.aspx?ID=2363 - https://api.publiccontractsscotland.gov.uk/v1/Notice?id=ocds-r6ebe6-0000841676 - https://scotcourts.gov.uk/the-courts/sheriff-court/about-sheriff-courts - https://www.gov.scot/policies/public-sector-procurement/community-benefits-in-procurement/ - https://www.nss.nhs.scot/procurement-and-logistics/sustainability/access-our-community-benefit-gateway/ - https://www.publictendersscotland.publiccontractsscotland.gov.uk/web/login.html ## Provenance This Markdown file is an alternate public rendering of the D3 Tenders contract record. The canonical page is https://d3tenders.com/contract/?ocid=ocds-r6ebe6-0000841676. The underlying structured data is available as OCDS JSON at https://d3tenders.com/contract/ocds-r6ebe6-0000841676.json.